Drugs / SAR441255
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04521738 | Apr → Sep 2019 | obesity disorder | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR441255 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04521738 ↗ |
| Action | Activate | “We developed SAR441255, a synthetic peptide agonist of the GLP-1, GCG, and GIP receptors, structurally based on the exendin-4 sequence.” PMID 34932984 ↗ Dec 2021 |
| Modality | Peptide | “We developed SAR441255, a synthetic peptide agonist of the GLP-1, GCG, and GIP receptors, structurally based on the exendin-4 sequence.” PMID 34932984 ↗ Dec 2021 |
| Route | Subcutaneous | “Route of administration: subcutaneous” NCT04521738 ↗ |